Congo - Health - Towards local production of medicines

The price of medicines is a barrier to access to quality healthcare for the majority of Congolese people. The government wants to increase private investment in pharmaceutical production.

Position

Reference

Space not available

Reserve this advertising space

Selected ad format

The file format is not recognized

Click here for
upload an ad

Click here to download
an announcement

Here drag and drop or
upload an ad

Send the ad up to 8 days after payment
A link will be sent to you by contact@via-agency.media

Reserved space
Announcement transmitted

If you want another location, you can move this ad

Reference

The signatory countries of the Lomé Initiative, including Congo, have decided to criminalize the trafficking of substandard and falsified medical products. Congo-Brazzaville intends to legalize the monopoly on the practice of qualified pharmacists and medical biologists and on provisions for the promotion of the national pharmaceutical industry.

In the market for drugs in bags of injectable solution for infusion, with a fleet of latest generation pharmaceutical machines using highly sophisticated technologies, the Biocare laboratory was established in Congo in 2012-2013 with the aim of meeting the needs of hospitals in terms of quality and quantity.

In April 2023, the pharmaceutical company Biogaran announced the expansion of its activities in the Dolisie region to democratize the use of quality generic medicines and expand its territorial coverage in the Republic of Congo, three years after its launch in Brazzaville and Pointe-Noire. Biogaran, the leader in generic medicines in France, markets a wide range of nearly 100 medicines in Congo, produced at 51% in France and 91% in Europe, making it possible to treat some of the most common pathologies in the country at a lower cost.

Position

Reference

Space not available

Reserve this advertising space

Selected ad format

The file format is not recognized

Click here for
upload an ad

Click here to download
an announcement

Here drag and drop or
upload an ad

Send the ad up to 8 days after payment
A link will be sent to you by contact@via-agency.media

Reserved space
Announcement transmitted

If you want another location, you can move this ad

Reference

The use of generic drugs is not thought to exceed 30% in Congo-Brazzaville, yet they are a preferred alternative. Meeting international standards, generic drugs are as effective as the original drug, but being much less expensive, they allow patients to access care at a lower cost. The WHO estimates that the use of generic drugs significantly reduces the cost of medicines for both governments and patients.

A significant and positive example of the impact of generic drugs is the changing prices of antiretroviral drugs used to treat HIV. According to the WHO, the cost of therapy per patient per year has fallen from $10,000 to less than $100 following the introduction of generic drugs, which has significantly increased access to treatment: in 2003, only 500,000 people were receiving this care, compared to 15.8 million in 2015. This represents a significant step forward in providing patients with access to treatment.

Regulatory harmonization and improvement of pharmacovigilance processes is an issue addressed by member countries of the Central African Economic and Monetary Community (CEMAC) and the West African Economic and Monetary Union (WAEMU).